The team leveraged a nationally representative cohort of 2,402 U.S. adults from the National Health and Nutrition Examination Survey (NHANES) collected between 1999 and 2002, coupled with mortality follow-up data extending through 2019. This extensive dataset allowed for an unprecedented evaluation of thirteen distinct DNA methylation clocks, alongside traditional clinical and behavioral mortality risk factors. DNA methylation clocks are advanced epigenetic algorithms trained to estimate biological age and aging rates based on methylation patterns at numerous genomic sites, reflecting cumulative molecular damage and dysregulation.

Among the examined epigenetic indicators, GrimAge2 emerged as the most robust mediator for social disparities in mortality, accounting for as much as 52% of the mortality gap observed between different occupational groups. This particular clock is notable for its training on plasma proteins and smoking history, components closely tied to cardiovascular and metabolic health, which are critical mortality determinants. The study also highlighted DunedinPoAm, a biomarker quantifying the pace of aging, which demonstrated strong mediation effects across various socioeconomic strata.

Intriguingly, the mediation power of DNA methylation clocks often surpassed that of classical clinical risk markers, including C-reactive protein and comprehensive cholesterol panels. This finding suggests that epigenetic clocks integrate the biophysiological embedding of diverse stressors—ranging from environmental exposures and psychosocial stress to metabolic dysfunction—capturing a multi-systemic biological aging signature far beyond the reach of conventional biomarkers. Such integrative capacity underscores their potential as powerful tools for dissecting the biological consequences of social adversity.

The researchers systematically dissected disparities by racial and ethnic identity, uncovering that Black and Hispanic participants exhibited significantly elevated all-cause mortality risk relative to White participants after adjusting for age and sex. Parallel patterns emerged for socioeconomic variables: individuals with lower educational attainment, reduced income levels, and blue-collar occupations faced heightened mortality risk. These social risk gradients in mortality were substantially mediated by epigenetic aging clocks, reflecting how social disadvantage translates into accelerated biological aging.

Notably, not all DNA methylation clocks behaved uniformly across groups, revealing a complex biological landscape. While physiologically trained clocks like GrimAge2 and DunedinPoAm robustly mediated mortality disparities, clocks linked to telomere biology occasionally exhibited inverse mediation effects, particularly among racial comparisons. These counterintuitive patterns may mirror biological resilience or adaptation mechanisms within certain populations and underscore the need for further research elucidating the nuanced interplay between social context, biology, and epigenetics.

This investigation amplifies the promise of epigenetic clocks as sophisticated integrative biomarkers capturing the cumulative burden of inflammation, metabolic stress, environmental toxicity, and lifestyle behavior through the lens of DNA methylation alterations. Unlike traditional biomarkers focused on isolated pathways, these clocks synthesize multifaceted inputs into a singular aging metric, enabling refined stratification of disease risk and mortality in population studies.

Despite offering compelling evidence, the authors are cautious, emphasizing the observational nature of their work and the constraint of cross-sectional methylation measurements, which limit causal inferences. They advocate for rigorous longitudinal studies to disentangle temporal dynamics between social exposures, biological aging trajectories, and mortality outcomes to more definitively establish causal pathways and mechanisms.

This study bridges social epidemiology and molecular biology, providing critical empirical support for the hypothesis that social inequalities become biologically ‘embedded’ through epigenetic aging processes. Such biomarkers could revolutionize public health surveillance and intervention by identifying at-risk populations based on biological aging metrics, potentially guiding precision preventive strategies aimed at mitigating social disparities in health and longevity.

Moreover, the evidence of epigenetic clock mediation in cardiovascular and cancer-specific mortality disparities spotlights distinct pathophysiological routes through which social determinants exert differential impacts on major causes of death. This stratification marks an important step towards precision medicine approaches that account for social context in disease risk modeling and therapeutic targeting.

The findings resonate with a growing body of literature positioning biological aging as a central node linking environmental, behavioral, and psychosocial factors with chronic disease development and mortality. DNA methylation clocks, by crystallizing these cumulative impacts into measurable biomarkers, open avenues for novel mechanistic insights and translational health applications spanning epidemiology, gerontology, and social medicine.

In conclusion, this seminal work by Shen and colleagues marks a significant advance in understanding the molecular underpinnings of health disparities. By quantifying the mediating role of DNA methylation aging biomarkers, the research illuminates how race, socioeconomic status, and occupational exposures become inscribed onto the epigenome, accelerating biological aging and elevating mortality risk. These insights hold profound implications for research, policy, and clinical practice aimed at achieving health equity through targeted interventions addressing the biological consequences of social determinants.

Subject of Research:
DNA methylation clocks, epigenetic aging, social determinants of health, mortality disparities

Article Title:
The mediating role of DNA methylation clocks in associations of race, ethnicity, education, income, and occupation with mortality: findings from NHANES 1999-2002

News Publication Date:
May 8, 2026

Web References:
DOI: 10.18632/aging.206377

Image Credits:
Copyright: © 2026 Shen et al. Distributed under Creative Commons Attribution License (CC BY 4.0)

Keywords:
Race and ethnicity, social position, epigenetic aging, mediation analysis, mortality disparities, DNA methylation, biological aging, health inequalities

Despite significant increases in average life expectancy globally, the extension of healthy years—those free from chronic illnesses and age-related decline—has lagged. The prevalence of chronic diseases escalates sharply with age, posing immense challenges to healthcare systems and diminishing quality of life. The ARPA-H funded initiative seeks to disrupt this paradigm by transitioning from a reactive medical approach that treats diseases after their onset to a proactive strategy focused on prevention of biological aging and decline before clinical symptoms emerge.

Dr. Belsky, a key figure affiliated with Columbia’s Robert N. Butler Columbia Aging Center, emphasizes the urgent need for objective and measurable biological signals that can demonstrate the efficacy of interventions targeting the aging process itself. Identification of such biomarkers would enable clinicians and researchers to assess in real-time whether treatments genuinely decelerate aging, thereby preserving health, functional independence, and quality of life in aging populations.

The five-year PROSPR program supports a landmark project known as FAST—Facilitating Aging Studies with Translational data—which represents a paradigm shift in geriatric medicine. Unlike traditional clinical trials that often focus on singular diseases or symptoms, the FAST initiative integrates and analyzes existing clinical trial datasets and biospecimens relating to medications with known geroprotective properties. This meta-analytic approach allows for the discovery of novel biomarkers that capture the multifaceted biology of aging and identify effective interventions.

FAST incorporates data from trials involving four out of five key classes of drugs prioritized for their potential to modulate fundamental aging processes: metformin, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and rapamycin. These pharmacological agents have been shown in preclinical studies to extend lifespan by targeting cellular and molecular pathways implicated in aging such as metabolic regulation, inflammation, and cellular senescence. Their broad-spectrum benefits in humans beyond their original therapeutic indications highlight their promise as modulators of biological aging.

Preliminary findings from analyses within the FAST framework are particularly compelling. Evidence suggests that rapamycin administration can slow ovarian aging by approximately 20%, potentially prolonging female fertility by up to five years. Additional data indicate improvements in cardiovascular biomarkers, enhancements in patient-reported outcomes relating to overall health status, and a measurable deceleration in progression to type 2 diabetes mellitus. These early results underscore FAST’s vast potential to uncover clinically meaningful effects of aging-modifying drugs.

Andrew Brack, the ARPA-H Program Manager and architect of the PROSPR initiative, underscores the essential role of biomarkers in expediting clinical research on aging. Because the aging process spans decades, clinical trials must rely on surrogate endpoints that demonstrate early biological responses to interventions. FAST’s comprehensive database and multimodal analysis pipeline provide a transformative platform to identify and validate such biomarkers, bridging a critical gap in translational geroscience.

The FAST project’s success hinges on a multidisciplinary consortium spanning multiple top-tier research institutions. Expertise ranges from aging biology and clinical pharmacology to proteomics, metabolomics, epigenetics, biostatistics, and computational biology, enabling sophisticated integration and interpretation of clinical and molecular data. Dr. Belsky serves as principal investigator while co-leads include Dr. Nir Barzilai of Albert Einstein College of Medicine and Dr. Mahdi Moqri of Brigham and Women’s Hospital. Columbia’s Zohn Rosen manages the project logistics and coordination.

Dr. Barzilai highlights the transformative potential of FAST to redefine how aging is measured and managed clinically. The program envisions a future in which older adults undergo routine biological age assessments, receive tailored interventions, and observe tangible rejuvenation within months. Simultaneously, pharmaceutical innovators will leverage FAST’s biomarker toolkit to accelerate the development and regulatory approval of next-generation gerotherapeutics, fundamentally altering the trajectory of healthcare for aging populations.

All data generated by FAST will be securely housed and made accessible to qualified researchers through the Columbia Data Platform (CDP), a cutting-edge cloud infrastructure operated by Redivis on Google Cloud. This data-sharing paradigm fosters open collaboration and rapid scientific discovery, positioning FAST as a global hub for aging research innovation.

Dr. Belsky reflects on the paradigm shift catalyzed by this initiative: “FAST is moving the science of aging from theoretical frameworks and animal models into actionable human biology. By harnessing data from diverse clinical trials, we have the unprecedented opportunity to pinpoint the biological signals that truly slow aging in humans—and pivot medicine toward prevention rather than reaction.”

Moreover, the project signifies a critical inflection point in geroscience research. Rather than segmenting diseases for treatment, FAST confronts the challenge of aging as a complex, systemic process. This holistic perspective is poised to redefine clinical practice in aging societies by focusing on extending the duration of healthy, functional years, thereby reducing the burden of age-associated morbidity and healthcare costs.

Originally incubated by the American Federation for Aging Research and co-led by Drs. Belsky, Barzilai, and Moqri, the FAST project includes a network of collaborators at Columbia University such as Aris Floratos in Systems Biology, Yousin Suh in Obstetrics and Gynecology, Zhonghua Liu in Biostatistics, and Gary Miller in Environmental Health Sciences. Partner institutions include Duke University, Saint Luke’s Health System, and industry collaborators like NovoNordisk, OLink Proteomics, and TruDiagnostic Epigenetics, reflecting a broad coalition across academia, healthcare, and biotechnology.

Columbia University Mailman School of Public Health serves as the academic home for FAST, leveraging its century-old legacy of interdisciplinary research and global public health impact. The Robert N. Butler Columbia Aging Center similarly contributes an integrative framework combining biosocial insights with policy and practical applications to meet the demands of an aging demographic.

This project epitomizes a new frontier in public health and preventive medicine, wherein the biological mysteries of aging are decoded and harnessed to extend healthy human longevity. By redefining how aging-related decline is measured and treated, the FAST initiative promises to usher in an era where living longer is accompanied by living better—free from the disabilities and chronic conditions that have long shadowed extra years of life.

Subject of Research: Biological hallmarks of aging; development and validation of biomarkers to measure and intervene upon the aging process in humans.

Article Title: Accelerating Healthy Aging: Columbia University’s FAST Initiative Harnesses Clinical Trial Data to Transform Geroscience

News Publication Date: February 24, 2026

Web References:
– Columbia University Mailman School of Public Health: www.mailman.columbia.edu
– Robert N. Butler Columbia Aging Center: aging.columbia.edu
– ARPA-H PROSPR Program: [Link to official ARPA-H PROSPR program site, if available]

Keywords: Aging biology, biomarkers, geroscience, clinical trials, metformin, rapamycin, SGLT-2 inhibitors, GLP-1 agonists, public health, preventive medicine, longevity, chronic disease prevention

The Center for SUNSHINE represents a pioneering confluence of disciplines including health policy, clinical medicine, economics, epidemiology, artificial intelligence, and health informatics, unified under a mission to redefine aging resilience. The initiative builds upon five decades of prior scholarly work from UMD’s renowned Center on Aging, leveraging computational innovations developed through the University of Maryland Institute for Health Computing (UM-IHC). This synergy of expertise aims to transform aging care systems by enhancing care coordination, empowering community-level involvement, and reconstructing health and social service frameworks to more effectively meet the needs of aging populations across the country.

At the helm of this ambitious enterprise is Dr. Jie Chen, professor and chair of the Department of Health Policy and Management at UMD and director of its Center on Aging. Dr. Chen leads a leadership triad including Dr. Rozalina McCoy, associate professor at the University of Maryland School of Medicine and director of UM-IHC’s Center for Population Health, alongside Dr. Stephen Thomas, a distinguished professor of health policy and management at UMD SPH. Together, this team integrates a holistic view of aging resilience, focusing on systemic transformation through interdisciplinary study and innovation. Their collective vision underscores the imperative of creating inclusive, sustainable care ecosystems that not only extend lifespan but imbed quality and dignity into the aging experience.

Central to the Center for SUNSHINE’s mandate is the harnessing of large-scale health data, including anonymized Medicare claims, electronic health records, and geospatial data, combined with analytic and modeling expertise. By enabling unprecedented access to these rich data resources, SUNSHINE empowers investigators nationwide to conduct pioneering research that informs evidence-based interventions and policy reforms. In addition to providing data access, the center offers tailored development and mentorship opportunities to emerging scholars, ensuring a robust pipeline of expertise dedicated to aging resilience and health systems innovation.

The center’s inclusion of expertise from fields as diverse as artificial intelligence and population health reflects a broader trend in gerontological research toward computationally sophisticated, data-driven approaches. AI and machine learning models are being advanced to predict health trajectories, optimize care delivery pathways, and identify social determinants that contribute to disparate aging outcomes. By integrating these technologies with clinical insights and policy analysis, SUNSHINE aims to develop scalable innovations capable of reshaping national standards for elder care.

Moreover, community engagement remains a pillar of SUNSHINE’s operational philosophy. Dr. Stephen Thomas emphasizes that older adults and their families are more than mere research subjects; they are vital collaborators who help shape research agendas, policy frameworks, and intervention strategies. This commitment to participatory research ensures that the center’s work remains relevant, responsive, and grounded in the lived realities of those it aims to serve. Such engagement enhances trust, cultural competence, and ultimately the effectiveness of health innovations designed for diverse aging populations.

In its immediate future, the center has prioritized two pilot projects with direct implications for health and wellbeing among older adults. One project, led by Dr. Shelby Steuart at UMD College Park, investigates the role of telehealth and behavioral health care modalities in expanding access and improving outcomes for older populations. This research is timely given the accelerated adoption of telemedicine catalyzed by the COVID-19 pandemic and the ongoing need to overcome barriers such as digital literacy and infrastructure gaps. The other pilot, spearheaded by Dr. Margaret Connolly at UMSOM, focuses on access to novel therapeutic interventions for chronic obstructive pulmonary disease (COPD), a prevalent and debilitating respiratory condition affecting many elders. Both pilots exemplify SUNSHINE’s commitment to actionable research with tangible clinical and social impact.

The organizational structure of the Center for SUNSHINE is extensive and collaborative, encompassing ten academic units within UMD, ranging from the School of Engineering to the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM). Partnerships extend beyond the university system, incorporating Howard University, the Erickson School of Aging Studies at the University of Maryland, Baltimore County (UMBC), and regional institutions like Georgetown University and Virginia Commonwealth University. National and community organizations such as the PATIENTS Program at UMB, Maryland CRAB, Maryland Extension, Encore Creativity for Older Adults, and AARP participate to ensure the center’s outreach and impact span academic, clinical, social, and policy domains.

This multi-institutional and multi-sector collaboration epitomizes the center’s interdisciplinary and translational approach. Addressing aging resilience necessitates not only robust research but also integrated education and training paradigms. The Center for SUNSHINE is committed to cultivating the next generation of scholars, providing mentorship and career development in aging-related health systems research. By doing so, it aims to perpetuate a cadre of informed professionals capable of navigating and influencing the evolving landscape of elder care.

Technological innovation is at the heart of the center’s strategic initiatives. The integration of geospatial analyses with health data promises new insights into how environments and social determinants impact aging processes and health outcomes. These spatial methodologies enable researchers to pinpoint areas of care inequity, identify community resources, and tailor interventions that reflect local contexts. As the field of aging research increasingly recognizes the interplay between biology, behavior, and environment, SUNSHINE’s analytical capabilities contribute essential dimensions to this complex picture.

From a policy perspective, the Center for SUNSHINE is positioned to inform reforms that enhance care coordination and resource allocation. By generating evidence on effective models of integrated care, economic analyses, and system efficiencies, the center’s work will support policymakers and health system leaders in making data-driven decisions that improve care delivery. This alignment of research and policy is crucial as the United States grapples with rising healthcare costs amid an aging populace demanding compassionate, accessible, and quality services.

In summary, the development of the Center for SUNSHINE marks a transformative moment in the national strategy to support healthy aging. Through its interdisciplinary, data-driven, and community-engaged framework, the center advances the frontiers of geriatric care, systems resilience, and health equity. Its commitment to fostering collaborative innovation promises to elevate the science of aging and forge new pathways toward empowering older adults to live healthier, fuller lives. As SUNSHINE continues to expand its research portfolio and deepen partnerships, it stands poised to become a vital national resource accelerating progress in aging science and care.

Subject of Research: Health systems innovation and aging resilience through interdisciplinary research and integrated care models.

Article Title: Center for SUNSHINE Pioneers Interdisciplinary Innovations to Transform Aging Resilience and Care Systems in America

News Publication Date: 2024

Web References:

• American Journal of Geriatric Psychiatry Article
• University of Maryland School of Public Health Center on Aging
• University of Maryland Institute for Health Computing

Image Credits: UMD